Company Name



VU University Medical Center Amsterdam

The company

DC4U is focused on developing products that enable targeting of tumor vaccines to dendritic cells (DC), the master regulators of the immune system. DC4U BV is hosted at the Department of Cell Biology and Immunology of the VUmc.

DC4U has entered a vaccine development program to design and test in-vivo strategies for DC activation directly in patients’ skin or lymph nodes. It’s developing glycol-liposomes that can be used for preclinical assessments. At the same time the company is developing new strategies to transfer its knowledge into the clinic. Candidate vaccines are being prepared for pre-clinical testing in ex vivo human skin explants models.